Compare Icl Group Ltd (ICL) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Icl Group Ltd vs Incyte Corporation — how do they compare? Icl Group Ltd trades at $5.02 (market cap $6.47B), while Incyte Corporation trades at $112.79 (market cap $22.85B). The key difference: Incyte Corporation is far larger — about 3.5× Icl Group Ltd's market cap, and Icl Group Ltd pays a 4.11% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Icl Group Ltd for 56 Days and Incyte Corporation for 33 Days on average.
| ICL | INCY | |
|---|---|---|
Market Cap | $6.47B | $22.85B |
Volume | 1,387,140 | 1,927,029 |
Sector | Basic Materials | Health |
52-Week High | $6.84 | $129.93 |
52-Week Low | $4.80 | $83.80 |
Typical Hold Time | 56 Days | 33 Days |
Enterprise Value | $9.11B | $18.35B |
Dividend Yield | 4.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICL trades at $5.02, down 1.18% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $0.12, beating estimates, but revenue and net income have declined from 2022 peaks. Valuation appears reasonable with P/E of 20.83 and P/S of 0.84, while analyst consensus is entirely Hold with a $6.08 price target. Recent news highlights dividend strength and cost-transformation initiatives.
The outlook is mixed: earnings beats and dividend yield offer support, but declining profitability and industry headwinds pose challenges. Upside exists if cost cuts and price stabilization materialize, though margin pressure and competitive threats remain key risks for investors.
Incyte (INCY) trades at $112.79, down 0.57% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $5.14B and net income of $1.29B, yielding robust profit margins of 92.62% gross and 27.71% net. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI highlight growth initiatives. Valuation metrics appear reasonable with P/E of 14.36 and P/S of 3.98, below sector averages in some cases.
The outlook remains positive with analyst consensus price target of $132.43 implying 17% upside, though near-term pressure exists from Q3 2026 expected EPS loss. Key risks include JAKAFI patent expiration post-2029 and execution on $4B sales target. Institutional sentiment leans bullish with 52% buy ratings, supporting the growth transition story despite technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
